The estimated Net Worth of Robert Baffi is at least $13.4 millió dollars as of 7 August 2018. Robert Baffi owns over 5,173 units of Biomarin Pharmaceutical stock worth over $6,094,156 and over the last 21 years Robert sold BMRN stock worth over $7,279,792.
Robert has made over 47 trades of the Biomarin Pharmaceutical stock since 2004, according to the Form 4 filled with the SEC. Most recently Robert sold 5,173 units of BMRN stock worth $543,165 on 7 August 2018.
The largest trade Robert's ever made was exercising 163,888 units of Biomarin Pharmaceutical stock on 10 March 2010 worth over $3,605,536. On average, Robert trades about 11,226 units every 53 days since 2004. As of 7 August 2018 Robert still owns at least 71,882 units of Biomarin Pharmaceutical stock.
You can see the complete history of Robert Baffi stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL, CA, 94901.
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over $153,109,113 worth of Biomarin Pharmaceutical stock and bought 151,118 units worth $2,557,509 . The most active insiders traders include Jean Jacques Bienaime, Mark J Enyedy és Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of $912,996. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth $64,260.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: